Qiagen N.V. (ETR:QIA)
Germany · Delayed Price · Currency is EUR | Market Cap | 6.11B -25.2% |
| Revenue (ttm) | 1.82B +4.8% |
| Net Income | 348.80M +329.3% |
| EPS | 1.68 +338.2% |
| Shares Out | n/a |
| PE Ratio | 17.51 |
| Forward PE | 13.65 |
| Dividend | 2.18 (7.40%) |
| Ex-Dividend Date | Jan 8, 2026 |
| Volume | 461,085 |
| Average Volume | 821,383 |
| Open | 29.51 |
| Previous Close | 29.78 |
| Day's Range | 29.15 - 29.91 |
| 52-Week Range | 27.56 - 47.60 |
| Beta | 0.64 |
| RSI | 43.17 |
| Earnings Date | May 6, 2026 |
About Qiagen
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purif... [Read more]
Financial Performance
In 2025, Qiagen's revenue was $2.09 billion, an increase of 5.65% compared to the previous year's $1.98 billion. Earnings were $424.88 million, an increase of 408.28%.
Financial numbers in USD Financial StatementsNews
Qiagen Digital Insights to integrate Nvidia accelerated computing
Qiagen (QGEN) announced at the 2026 BIO-IT World Conference & Expo in Boston that the Qiagen Digital Insights bioinformatics business and its curated knowledge bases and bioinformatics expertise will ...
QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA
VENLO, Netherlands & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced at the 2026 BIO-IT World Conference & Expo in Boston that the...
Qiagen price target lowered to $36 from $50 at Stifel
Stifel lowered the firm’s price target on Qiagen (QGEN) to $36 from $50 and keeps a Hold rating on the shares citing a lower growth outlook after the company started…
Qiagen Transcript: Bank of America Global Healthcare Conference 2026
Board changes and a CEO search are underway, with new share buybacks and a 40% dividend increase proposed. Guidance was revised due to a drop in U.S. immigration-related QuantiFERON sales, but other growth pillars and new product launches are on track. Operating margin targets and midterm growth goals remain intact.
Qiagen Slides: FY 2026
Qiagen has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 12, 2026.
QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced proposals for its 2026 Annual General Meeting, including plans to appoint co-f...
Qiagen price target lowered to $40 from $46 at TD Cowen
TD Cowen analyst Dan Brennan lowered the firm’s price target on Qiagen (QGEN) to $40 from $46 and keeps a Hold rating on the shares. The firm updated its model…
Qiagen Transcript: Status update
Latent TB testing is a rapidly growing market with significant conversion potential from traditional skin tests. New innovations include faster, fully automated workflows and an AI tool for risk stratification, all exclusive to QuantiFERON. Customer feedback is strong, and the company remains confident in its 2028 financial targets.
Qiagen Slides: Status update
Qiagen has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Qiagen Slides: Investor presentation
Qiagen has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to advance its QuantiFERON latent tuberculosis (TB) test with a new...
Qiagen reports Q1 EPS 54c, consensus 54c
Reports Q1 revenue $492M, one estimate $499.2M. “QIAGEN (QGEN) made important progress across many areas of the portfolio in the first quarter, led by solid sales growth in Sample technologies,…
QIAGEN Reports Full Results for Q1 2026
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today reports full results for the first quarter of 2026 in line with the preliminary ann...
Qiagen Earnings release: Q1 2026
Qiagen released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Qiagen price target lowered to $43 from $54 at Deutsche Bank
Deutsche Bank analyst Jan Koch lowered the firm’s price target on Qiagen (QGEN) to $43 from $54 and keeps a Buy rating on the shares.
Qiagen price target lowered to EUR 34 from EUR 44 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Qiagen (QGEN) to EUR 34 from EUR 44 and keeps an Equal Weight rating on the shares.
Qiagen price target lowered to $45 from $60 at JPMorgan
JPMorgan lowered the firm’s price target on Qiagen (QGEN) to $45 from $60 and keeps an Overweight rating on the shares.
Qiagen price target lowered to $38 from $55 at Citi
Citi lowered the firm’s price target on Qiagen (QGEN) to $38 from $55 and keeps a Neutral rating on the shares.
Qiagen price target lowered to $38 from $44 at Barclays
Barclays analyst Luke Sergott lowered the firm’s price target on Qiagen (QGEN) to $38 from $44 and keeps an Equal Weight rating on the shares following the earnings report and…
Qiagen upgraded to Outperform from Neutral at Baird
Baird upgraded Qiagen (QGEN) to Outperform from Neutral with a price target of $43, down from $53. The company’s Q1 results missed expectations driven by weaker QuantiFERON demand for immigration…
Qiagen N.V. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Qiagen N.V. (NYSE: QGEN). The investigation focuses on Qiagen's executive...
Qiagen Transcript: Investor update
Q1 2026 delivered adjusted EPS in line with outlook, but sales missed targets due to lower QuantiFERON immigration testing and cautious U.S. life sciences demand. 2026 guidance was revised down for both sales and EPS, but strong growth is expected in H2 from new launches and efficiency gains.
Qiagen Slides: Investor update
Qiagen has posted slides in relation to its latest quarterly earnings report, which was published on April 28, 2026.
Qiagen Earnings release: Investor update
Qiagen released its earnings on April 28, 2026, summarizing the period's financial results.
Qiagen cuts FY26 EPS view to ‘at least’ $2.43 from ‘at least’ $2.50
Consensus $2.51. The company states: “QIAGEN (QGEN) has updated its full-year 2026 outlook for net sales growth of about 1-2% CER (previously at least 5% CER growth). Key factors include…